CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 176.31 AUD -0.22% Market Closed
Market Cap: 85.5B AUD

EV/EBITDA
Enterprise Value to EBITDA

12.7
Current
21.9
Median
6.3
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
12.7
=
Enterprise Value
98.3B AUD
/
EBITDA
5.1B USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBITDA: 40.4
12.7
8%
1.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 430.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
11%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163.9
N/A N/A
NL
argenx SE
XBRU:ARGX
59
807%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.2 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
11.7
2-Years Forward
EV/EBITDA
10.9
3-Years Forward
EV/EBITDA
10.1